Results 211 to 220 of about 2,984,799 (310)

Real-world insights into safety, tolerability, and predictive factors of adverse drug reactions in treating idiopathic pulmonary fibrosis with pirfenidone and nintedanib. [PDF]

Ther Adv Drug Saf
Provenzani A, Leonardi Vinci D, Alaimo M, Di Maria S, Tuzzolino F, Floridia G, Di Stefano R, Carollo A, Callari A, Polidori P, Vitulo P.   +10 more
europepmc   +1 more source

Inhibiting the Histone Demethylase Kdm4a Restrains Cardiac Fibrosis After Myocardial Infarction by Promoting Autophagy in Premature Senescent Fibroblasts

Advanced Science, EarlyView.
Kdm4a downregulation restrains excessive cardiac interstitial fibrosis and remodeling by depressing the premature senescence of fibroblasts in the advanced stage after MI but does not affect early ventricular rupture. It verified that Kdm4a downregulation promotes autophagy in premature senescent fibroblasts by increasing the H3K9m3 modification of the
Ming Jin, Chuling Li, Zhaoyi Wu, Zhenquan Tang, Jingfang Xie, Guoquan Wei, Zhiwen Yang, Senlin Huang, Yijin Chen, Xinzhong Li, Yanmei Chen, Wangjun Liao, Yulin Liao, Guojun Chen, Hao Zheng, Jianping Bin   +15 more
wiley   +1 more source

Periorbital edema and phototoxic rash associated with dasatinib: A case report. [PDF]

SAGE Open Med Case Rep
Ugurlu BO, Malkan UY.
europepmc   +1 more source

Activation of HTR2B Suppresses Osteosarcoma Progression through the STAT1‐NLRP3 Inflammasome Pathway and Promotes OASL1+ Macrophage Production to Enhance Antitumor Immunity

Advanced Science, EarlyView.
Activation of HTR2B suppresses osteosarcoma progression through the STAT1‐NLRP3 inflammasome pathway and promotes OASL1+ Macrophage production to enhance anti‐tumor immunity. Abstract Osteosarcoma is a primary malignant bone tumor originating from mesenchymal tissue, and associated with poor prognosis.
Zhen Huang, Jiazhuang Zhu, Jianping Hu, Xingkai Wang, Xiaolong Ma, Enjie Xu, Kunpeng Zhu, Chunlin Zhang   +7 more
wiley   +1 more source

Chemotherapy-related adverse drug reaction and associated factors among adult cancer patient attending Jimma medical center oncology unit, Southwest Ethiopia. [PDF]

PLoS One
Shrmeka MS, Semman MF, Moges BT, Dereja FN, Garedo AW.   +4 more
europepmc   +1 more source

In Vivo Reprogramming of Tissue‐Derived Extracellular Vesicles for Treating Chronic Tissue Injury Through Metabolic Engineering

Advanced Science, EarlyView.
Inspired by exercise‐induced metabolic rewiring and EV secretion, this study shows that in vivo metabolic engineering strategy can reprogram EV secretion pattern and simultaneously attenuate multiple tissue injury in CKD status, highlighting that it is a potential strategy for treating diverse chronic diseases.
Meng Zhao, Shuyun Liu, Yizhuo Wang, Peng Lou, Ke Lv, Tian Wu, Lan Li, Qianyi Wu, Jiaying Zhu, Yanrong Lu, Meihua Wan, Jingping Liu   +11 more
wiley   +1 more source

Impact of Side Effects on Anemia Therapy Compliance. [PDF]

Nutrients
Ciont C, Pop RM, Pop L, Vodnar DC, Morariu ID, Suharoschi R, Pop OL.   +6 more
europepmc   +1 more source

IR783‐Stabilized Nanodrugs Enhance Anticancer Immune Response by Synergizing Oxidation Therapy and Epigenetic Modulation

Advanced Science, EarlyView.
IR783‐stabilized nanodrugs composed of NIR dye IR783, ROS inducer β‐lapachone, and epigenetic modulator CUDC101 are designed for breast cancer immunotherapy. The nanodrugs can not only promote cancer cell apoptosis through HDAC inhibition‐enhanced oxidation therapy but also reshape the immunosuppressive microenvironment, which provides a novel strategy
Jinzhao Liu, Meicen Wu, Qingyang Lyu, Chang Yang, Ni Fan, Kang Chen, Weiping Wang   +6 more
wiley   +1 more source

A Closer Look at the Dermatological Profile of GLP-1 Agonists. [PDF]

Diseases
Persson C, Eaton A, Mayrovitz HN.
europepmc   +1 more source

Enhancer Extrachromosomal Circular DNA ANKRD28 Elicits Drug Resistance via POU2F2‐Mediated Transcriptional Network in Multiple Myeloma

Advanced Science, EarlyView.
Enhancer eccANKRD28‐manipulated MM cells have been demonstrated to facilitate drug resistance and promote MM progression by activating the key transcription factor, POU2F2. POU2F2 interacts with sequence‐specific eccANKRD28 as well as RUNX1 and RUNX2 motifs to form the protein complex, which activates the promoter of oncogenes (IRF4, JUNB, IKZF3, et al.
Binzhen Chen, Jia Liu, Yaoxin Zhang, Changming Shi, Di Zhu, Guoqiang Zhang, Fei Xiao, Lu Zhong, Minyue Zhang, Lai Guan Ng, Honghui Huang, Tingting Lu, Jian Hou   +12 more
wiley   +1 more source